These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1007 related items for PubMed ID: 10762286

  • 1. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, Lucci R, Lombardi G.
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [Abstract] [Full Text] [Related]

  • 2. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
    Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G.
    J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
    [Abstract] [Full Text] [Related]

  • 3. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
    de Herder WW, Reijs AE, Kwekkeboom DJ, Hofland LJ, Nobels FR, Oei HY, Krenning EP, Lamberts SW.
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
    [Abstract] [Full Text] [Related]

  • 4. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. (99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy.
    Colao A, Ferone D, Lombardi G, Lastoria S.
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):713-21. PubMed ID: 12072040
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
    Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G.
    J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of quinagolide (CV 205-502), a selective D2-agonist, on vascular reactivity in patients with a prolactin-secreting adenoma.
    Bodmer CW, Atkin SL, Savage MW, Masson EA, White MC.
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):49-53. PubMed ID: 7641411
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E, Camanni F.
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.
    Andersen M, Bjerre P, Schrøder HD, Edal A, Høilund-Carlsen PF, Pedersen PH, Hagen C.
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):23-30. PubMed ID: 11167922
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, Colosimo C.
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [Abstract] [Full Text] [Related]

  • 18. Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas.
    de Herder WW, Reijs AE, de Swart J, Kaandorp Y, Lamberts SW, Krenning EP, Kwekkeboom DJ.
    Eur J Nucl Med; 1999 Jan; 26(1):46-50. PubMed ID: 9933661
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
    Manuchehri AM, Sathyapalan T, Lowry M, Turnbull LW, Rowland-Hill C, Atkin SL.
    Pituitary; 2007 Jan; 10(3):261-6. PubMed ID: 17557207
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.